Top

Graefe's Archive for Clinical and Experimental Ophthalmology

30-04-2024 | Magnetic Resonance Imaging | Inflammatory Disorders

Peripheral CD3⁺CD4⁺ T cells as indicators of disease activity in thyroid eye disease: age-dependent significance

Authors: Haiyang Zhang, Lianfei Fang, Yumeng Cheng, Yuhang Peng, Hui Wang, Mengda Jiang, Ling Zhu, Yinwei Li, Sijie Fang, Huifang Zhou, Jing Sun, Xuefei Song

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology

Abstract

Purpose

To provide an in-depth analysis of the association of peripheral lymphocytes and the disease activity of thyroid eye disease (TED).

Methods

This retrospective study enrolled 65 active TED patients and 46 inactive TED patients. Comparative analyses of peripheral lymphocyte subsets were conducted between active and inactive patients. Subgroup analyses were performed based on sex, age, disease duration, and severity. Correlation analyses explored the associations between lymphocyte subsets and TED activity indicators. Prediction models for TED activity were established using objective indicators.

Results

Significantly elevated levels of CD3⁺CD4⁺ T cells were observed in active TED patients compared to inactive patients (P = 0.010). Subgroup analyses further revealed that this disparity was most prominent in females (P = 0.036), patients aged 50 years and younger (P = 0.003), those with long-term disease duration (P = 0.022), and individuals with moderate-to-severe disease (P = 0.021), with age exerting the most substantial impact. Subsequent correlation analysis confirmed the positive association between CD3⁺CD4⁺ T cells and the magnetic resonance imaging indicator of TED activity among patients aged 50 years and younger (P = 0.038). The combined prediction models for TED activity, established using objective indicators including CD3⁺CD4⁺ T cells, yielded areas under curve of 0.786 for all patients and 0.816 for patients aged 50 years and younger.

Conclusions

Peripheral CD3⁺CD4⁺ T cells are associated with disease activity of TED, especially in patients aged 50 years and younger. Our study has deepened the understanding of the peripheral T cell profiles in TED patients.

Bartalena L, Tanda ML (2022) Current concepts regarding Graves’ orbitopathy. J Intern Med 292:692–716. https://doi.org/10.1111/joim.13524CrossRefPubMedPubMedCentral

Bahn RS (2010) Graves’ ophthalmopathy. N Engl J Med 362:726–738. https://doi.org/10.1056/NEJMra0905750CrossRefPubMedPubMedCentral

Menconi F, Marcocci C, Marinò M (2014) Diagnosis and classification of Graves’ disease. Autoimmun Rev 13:398–402. https://doi.org/10.1016/j.autrev.2014.01.013CrossRefPubMed

Gianoukakis AG, Khadavi N, Smith TJ (2008) Cytokines, Graves’ disease, and thyroid-associated ophthalmopathy. Thyroid 18:953–958. https://doi.org/10.1089/thy.2007.0405CrossRefPubMedPubMedCentral

Bartalena L, Fatourechi V (2014) Extrathyroidal manifestations of Graves’ disease: a 2014 update. J Endocrinol Invest 37:691–700. https://doi.org/10.1007/s40618-014-0097-2CrossRefPubMed

Mourits MP, Prummel MF, Wiersinga WM, Koornneef L (1997) Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy. Clin Endocrinol (Oxf) 47:9–14. https://doi.org/10.1046/j.1365-2265.1997.2331047.xCrossRefPubMed

Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P, Marcocci C, Mourits M, Perros P, Boboridis K, Boschi A, Currò N, Daumerie C, Kahaly GJ, Krassas GE, Lane CM, Lazarus JH, Marinò M, Nardi M, Neoh C, Orgiazzi J, Pearce S, Pinchera A, Pitz S, Salvi M, Sivelli P, Stahl M, von Arx G, Wiersinga WM (2008) Consensus statement of the European Group on Graves’ orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 158:273–285. https://doi.org/10.1530/eje-07-0666CrossRefPubMed

Zhang H, Fan J, Qu J, Han Q, Zhou H, Song X (2023) Predictive markers for anti-inflammatory treatment response in thyroid eye disease. Front Endocrinol 14:1292519. https://doi.org/10.3389/fendo.2023.1292519CrossRef

Zhang H, Lu T, Liu Y, Jiang M, Wang Y, Song X, Fan X and Zhou H (2023) Application of quantitative MRI in thyroid eye disease: imaging techniques and clinical practices. J Magn Reson Imaging. https://doi.org/10.1002/jmri.29114

10.

Lytton SD, Ponto KA, Kanitz M, Matheis N, Kohn LD, Kahaly GJ (2010) A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves’ orbitopathy. J Clin Endocrinol Metab 95:2123–2131. https://doi.org/10.1210/jc.2009-2470CrossRefPubMed

11.

Wakelkamp IM, Bakker O, Baldeschi L, Wiersinga WM, Prummel MF (2003) TSH-R expression and cytokine profile in orbital tissue of active vs. inactive Graves’ ophthalmopathy patients. Clin Endocrinol (Oxf) 58:280–287. https://doi.org/10.1046/j.1365-2265.2003.01708.xCrossRefPubMed

12.

Li H, Wang B, Li Q, Li Q, Qiao J, Lin D, Sui C, Ye L, Zhai H, Jiang B, Wang N, Han B, Jiang M, Tao X, Shao Z, Zhu C, Ma Y, Xiong P, Sun J, Zhou H, Lu Y (2023) T cell subsets are associated with clinical activity and efficacy of 4.5g intravenous glucocorticoid for moderate-to-severe thyroid-associated ophthalmopathy. Endocr Res 48:55–67. https://doi.org/10.1080/07435800.2023.2219734CrossRefPubMed

13.

Huang Y, Fang S, Li D, Zhou H, Li B, Fan X (2019) The involvement of T cell pathogenesis in thyroid-associated ophthalmopathy. Eye (Lond) 33:176–182. https://doi.org/10.1038/s41433-018-0279-9CrossRefPubMed

14.

Hwang CJ, Afifiyan N, Sand D, Naik V, Said J, Pollock SJ, Chen B, Phipps RP, Goldberg RA, Smith TJ, Douglas RS (2009) Orbital fibroblasts from patients with thyroid-associated ophthalmopathy overexpress CD40: CD154 hyperinduces IL-6, IL-8, and MCP-1. Invest Ophthalmol Vis Sci 50:2262–2268. https://doi.org/10.1167/iovs.08-2328CrossRefPubMed

15.

Rotondo Dottore G, Torregrossa L, Caturegli P, Ionni I, Sframeli A, Sabini E, Menconi F, Piaggi P, Sellari-Franceschini S, Nardi M, Latrofa F, Vitti P, Marcocci C, Basolo F, Marinò M (2018) Association of T and B cells infiltrating orbital tissues with clinical features of graves orbitopathy. JAMA Ophthalmol 136:613–619. https://doi.org/10.1001/jamaophthalmol.2018.0806CrossRefPubMedPubMedCentral

16.

Fang S, Huang Y, Zhong S, Li Y, Zhang Y, Li Y, Sun J, Liu X, Wang Y, Zhang S, Xu T, Sun X, Gu P, Li D, Zhou H, Li B, Fan X (2017) Regulation of orbital fibrosis and adipogenesis by pathogenic Th17 cells in graves orbitopathy. J Clin Endocrinol Metab 102:4273–4283. https://doi.org/10.1210/jc.2017-01349CrossRefPubMed

17.

Fang S, Huang Y, Wang N, Zhang S, Zhong S, Li Y, Sun J, Liu X, Wang Y, Gu P, Li B, Zhou H, Fan X (2019) Insights into local orbital immunity: evidence for the involvement of the Th17 cell pathway in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 104:1697–1711. https://doi.org/10.1210/jc.2018-01626CrossRefPubMed

18.

Hu H, Liang L, Ge Q, Jiang X, Fu Z, Liu C, Long J (2022) Correlation between peripheral T cell subsets and the activity of thyroid-associated ophthalmopathy. Int J Endocrinol 2022:2705650. https://doi.org/10.1155/2022/2705650CrossRefPubMedPubMedCentral

19.

Tollerud DJ, Clark JW, Brown LM, Neuland CY, Pankiw-Trost LK, Blattner WA, Hoover RN (1989) The influence of age, race, and gender on peripheral blood mononuclear-cell subsets in healthy nonsmokers. J Clin Immunol 9:214–222. https://doi.org/10.1007/bf00916817CrossRefPubMed

20.

Abdullah M, Chai PS, Chong MY, Tohit ER, Ramasamy R, Pei CP, Vidyadaran S (2012) Gender effect on in vitro lymphocyte subset levels of healthy individuals. Cell Immunol 272:214–219. https://doi.org/10.1016/j.cellimm.2011.10.009CrossRefPubMed

21.

Laurence J (1993) T-cell subsets in health, infectious disease, and idiopathic CD4+ T lymphocytopenia. Ann Intern Med 119:55–62. https://doi.org/10.7326/0003-4819-119-1-199307010-00010CrossRefPubMed

22.

Bartalena L (2013) Diagnosis and management of Graves disease: a global overview. Nat Rev Endocrinol 9:724–734. https://doi.org/10.1038/nrendo.2013.193CrossRefPubMed

23.

Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, Marinò M, Vaidya B, Wiersinga WM (2021) The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. Eur J Endocrinol 185:G43–G67. https://doi.org/10.1530/EJE-21-0479CrossRefPubMed

24.

Liu X, Su Y, Jiang M, Fang S, Huang Y, Li Y, Zhong S, Wang Y, Zhang S, Wu Y, Sun J, Fan X, Zhou H (2021) Application of magnetic resonance imaging in the evaluation of disease activity in graves’ ophthalmopathy. Endocr Pract 27:198–205. https://doi.org/10.1016/j.eprac.2020.09.008CrossRefPubMed

25.

Hu H, Xu XQ, Wu FY, Chen HH, Su GY, Shen J, Hong XN, Shi HB (2016) Diagnosis and stage of Graves’ ophthalmopathy: efficacy of quantitative measurements of the lacrimal gland based on 3-T magnetic resonance imaging. Exp Ther Med 12:725–729. https://doi.org/10.3892/etm.2016.3389CrossRefPubMedPubMedCentral

26.

Berger M, Matlach J, Pitz S, Berres M, Axmacher F, Kahaly GJ, Brockmann MA, Müller-Eschner M (2022) Imaging of the medial rectus muscle predicts the development of optic neuropathy in thyroid eye disease. Sci Rep 12:6259. https://doi.org/10.1038/s41598-022-10043-zCrossRefPubMedPubMedCentral

27.

Chen L, Hu H, Chen HH, Chen W, Wu Q, Wu FY, Xu XQ (2021) Usefulness of two-point Dixon T2-weighted imaging in thyroid-associated ophthalmopathy: comparison with conventional fat saturation imaging in fat suppression quality and staging performance. Br J Radiol 94:20200884. https://doi.org/10.1259/bjr.20200884CrossRefPubMed

28.

Huang Y, Wu Y, Zhang S, Lu Y, Wang Y, Liu X, Zhong S, Wang Y, Li Y, Sun J, Fang S, Zhou H (2022) Immunophenotype of lacrimal glands in graves orbitopathy: implications for the pathogenesis of Th1 and Th17 immunity. Thyroid 32:949–961. https://doi.org/10.1089/thy.2021.0671CrossRefPubMed

29.

Han R, Smith TJ (2006) T helper type 1 and type 2 cytokines exert divergent influence on the induction of prostaglandin E2 and hyaluronan synthesis by interleukin-1beta in orbital fibroblasts: implications for the pathogenesis of thyroid-associated ophthalmopathy. Endocrinology 147:13–19CrossRefPubMed

30.

Wang Y, Chen Z, Wang T, Guo H, Liu Y, Dang N, Hu S, Wu L, Zhang C, Ye K, Shi B (2021) A novel CD4+ CTL subtype characterized by chemotaxis and inflammation is involved in the pathogenesis of Graves’ orbitopathy. Cell Mol Immunol 18:735–745. https://doi.org/10.1038/s41423-020-00615-2CrossRefPubMedPubMedCentral

31.

Moulton VR (2018) Sex hormones in acquired immunity and autoimmune disease. Front Immunol 9:2279. https://doi.org/10.3389/fimmu.2018.02279CrossRefPubMedPubMedCentral

32.

Markle JGM, Frank DN, Mortin-Toth S, Robertson CE, Feazel LM, Rolle-Kampczyk U, von Bergen M, McCoy KD, Macpherson AJ, Danska JS (2013) Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity. Science 339:1084–1088. https://doi.org/10.1126/science.1233521

33.

Dolman PJ (2021) Dysthyroid optic neuropathy: evaluation and management. J Endocrinol Invest 44:421–429. https://doi.org/10.1007/s40618-020-01361-yCrossRefPubMed

34.

Goronzy JJ, Weyand CM (2012) Immune aging and autoimmunity. Cell Mol Life Sci:CMLS 69:1615–1623. https://doi.org/10.1007/s00018-012-0970-0CrossRefPubMed

35.

Li H, Zhu L, Wang R, Xie L, Ren J, Ma S, Zhang W, Liu X, Huang Z, Chen B, Li Z, Feng H, Liu G-H, Wang S, Qu J, Su W (2022) Aging weakens Th17 cell pathogenicity and ameliorates experimental autoimmune uveitis in mice. Protein Cell 13:422–445. https://doi.org/10.1007/s13238-021-00882-3CrossRefPubMed

36.

Levy N, Leiba H, Landau K, Zloto O, Huna-Baron R (2022) Clinical profile of 80-year-old and older thyroid eye disease patients. Graefes Arch Clin Exp Ophthalmol 260:2727–2736. https://doi.org/10.1007/s00417-022-05627-4

37.

Su Y, Liu X, Fang S, Huang Y, Li Y, Zhong S, Wang Y, Zhang S, Zhou H, Sun J, Fan X (2022) Age-related difference in extraocular muscles and its relation to clinical manifestations in an ethnically homogenous group of patients with Graves’ orbitopathy. Graefes Arch Clin Exp Ophthalmol 260:583–589. https://doi.org/10.1007/s00417-021-05377-9CrossRefPubMed

38.

Smith TJ, Hegedüs L, Lesser I, Perros P, Dorris K, Kinrade M, Troy-Ott P, Wuerth L, Nori M (2023) How patients experience thyroid eye disease. Front Endocrinol 14:1283374. https://doi.org/10.3389/fendo.2023.1283374CrossRef

39.

Perros P, Žarković M, Pearce SH, Razvi S, Kolli H, Dickinson AJ (2023) Inter-observer variability of clinical activity score: assessments in patients with thyroid eye disease. Am J Ophthalmol 252. https://doi.org/10.1016/j.ajo.2023.03.027

40.

Olejarz M, Szczepanek-Parulska E, Ostałowska-Klockiewicz A, Antosik P, Sawicka-Gutaj N, Helak-Łapaj C, Stopa M, Ruchala M (2023) High IgG4 serum concentration is associated with active Graves orbitopathy. Front Endocrinol 14:1083321. https://doi.org/10.3389/fendo.2023.1083321CrossRef

Title: Peripheral CD3+CD4+ T cells as indicators of disease activity in thyroid eye disease: age-dependent significance
Authors: Haiyang Zhang
Lianfei Fang
Yumeng Cheng
Yuhang Peng
Hui Wang
Mengda Jiang
Ling Zhu
Yinwei Li
Sijie Fang
Huifang Zhou
Jing Sun
Xuefei Song
Publication date: 30-04-2024
Publisher: Springer Berlin Heidelberg
Keywords: Magnetic Resonance Imaging
Magnetic Resonance Imaging
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-024-06496-9

At a glance: The STEP trials

Springer Medicine

Peripheral CD3⁺CD4⁺ T cells as indicators of disease activity in thyroid eye disease: age-dependent significance

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content